ICH GCP / Clinical Trials Registry · Jan 2026
Clinical-trial registry entry describing a study of the Q-Pad hrHPV test system for cervical screening and precancer detection using at-home menstrual samples.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Qvin (Qurasense, Inc.) is a Menlo Park-based women’s-health biotechnology company that developed the Q-Pad, an FDA-cleared diagnostic menstrual pad and at-home test kit that turns menstrual blood into lab reports for non-invasive health monitoring.
Primary product
Q-Pad diagnostic menstrual pad / at-home A1c test kit
Founded
2014
Headquarters
Menlo Park, California, United States
Team size
10-20
Industry
Biotechnology Research
Sub-industry
Women’s health diagnostics / femtech
Offices
3517 Edison Way, Menlo Park, CA 94025
405 El Camino Real, Menlo Park, CA 94025
Menlo Park, California, United States
Business model
At-home diagnostic test kits
CLIA-lab processing and reporting
Direct-to-consumer e-commerce
Research partnerships / clinical studies
Funding
Stage
Series A
Total raised
$12.4M
Latest round
Convertible Note · Apr 2024
Apr 2024 · StartX Accelerator
Oct 2020 · Y Combinator Continuity Fund
Sep 2019
Jul 2018 · Y Combinator
People & investors
Leadership
Co-Founder & CEO
COO & Co-Founder
Co-CEO
VP of Research and Development
Head of Lab
Work & culture
Mission-driven and hard-working, with a relaxed office atmosphere, autonomy, and a stated emphasis on work-life balance; the team also signals willingness to push hard when needed.
Compensation
Public job material signals a compensation package plus equity, with medical and dental coverage (including dependents up to 80%) and generous vacation and parental leave; no public salary bands were found.
Benefits
Compensation package
Equity plan
Medical insurance
Dental insurance
Dependent coverage up to 80%
Generous vacation
Parental leave
Menlo Park office
Product & market
Pricing
Direct-to-consumer test-kit sales centered on the Q-Pad A1c kit; public coverage shows the kit sold online, with no public insurance coverage signal.
Differentiators
- —FDA-cleared diagnostic menstrual pad
- —Non-invasive at-home self-collection
- —Uses menstrual blood as a recurring biospecimen
- —Lab results delivered through the Qvin app
- —Research-backed biomarker validation for A1c and other markers
- —Lower-barrier alternative to traditional blood draws
Technology
Angular
Appium
Dart
Flutter
Envoy
Gatsby
GitLab
Google Cloud
Grafana
Kubernetes
Microservices
Prometheus
Python
React
Sentry
Spring
Stripe
Customers
People who menstruate
People with diabetes
Healthcare organizations and diagnostic platforms
Scientists and research partners
Country-level agencies / public health partners
Competitors
NextGen Jane
Inito
Mira
Glow
kegg
Babyscripts
Wildflower Health
Delfina
Scale & contact
Estimated revenue
$1M-$10M
Estimated monthly visits
3K
Latest news
The Guardian · Oct 2025
Long-form feature discussing Qvin as one of the leading startups pursuing menstrual-blood diagnostics for women’s health.
Femtech Insider · Jan 2024
Coverage of Qvin’s FDA clearance, the CLIA-lab workflow, and the company’s broader biomarker ambitions in women’s health.
WWD · Jan 2024
Consumer-facing coverage noting the Q-Pad A1c kit’s public launch and reported $49 price point.
PR Newswire · Jan 2024
Press release announcing FDA clearance of the Q-Pad and A1c test, enabling at-home menstrual-blood-based A1c monitoring and broader biomarker testing.
Jobs and careers at Qvin
0 jobs at Qvin
No open positions
Check back later for new openings